An open-label, fixed-sequence, single, and multiple oral dose study to investigate the effect of multiple doses of vatiquinone on the single-dose PK of tolbutamide (CYP2C9) and omeprazole (CYP2C19)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Vatiquinone (Primary) ; Omeprazole; Tolbutamide
Indications Epilepsy; Friedreich's ataxia; Leigh disease; Methylmalonic acidaemia; Mitochondrial disorders; Noise-induced hearing loss; Parkinson's disease; Rett syndrome
Focus Pharmacokinetics

30 Sep 2022 New trial record
27 Sep 2022 Results published in the European Journal of Clinical Pharmacology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com